Objective:

To investigate how missense mutations in prostate cancer affect the proteome using a proteogenomic approach.

Approach:

• Methodology: Integrated SILAC-based quantitative mass spectrometry with curated mutation databases to map the impact of missense variants across prostate tumor and healthy tissues.

Key Findings:

• Proteins with mutations showed significant reductions in abundance, particularly in metabolic and stress-response pathways.
• Variant-enriched proteins clustered in oncogenic processes such as apoptosis suppression and immune modulation.
• Recurrent alterations were found in genes including ACTB, PPIF, and HSPA9, with several mutations predicted to destabilize protein function.

Interpretation:

The study demonstrates how genetic alterations translate into measurable proteomic shifts, supporting the role of proteogenomics in precision oncology.

Limitations:

• Challenges in ensuring correct pairing between mutated and non-mutated peptides.
• Technical difficulties in integrating genomic and proteomic data.

Conclusion:

The study identifies new candidate biomarkers and potential therapeutic targets in prostate cancer.

Sources:

• Oncology Advances